PT141
PT-141
A cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, and a metabolite of melanotan II — it differs from melanotan II by a C-terminal hydroxyl in place of the amide. It is an agonist at melanocortin receptors, with reported activity at MC1R, MC3R and MC4R.
PT-141 has 10 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 2,644 planned or enrolled participants across the 9 studies that published a figure. An FDA-approved product contains PT-141 — VYLEESI (AUTOINJECTOR) (NDA210557). 72 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names PT-141; the registry search is fuzzy, so every match is re-checked. None of this says whether PT-141 works or is safe.
FDA status
Approved
Human studies
10
Furthest phase
Phase 4
Papers, 10 yr
72
Readership
9,091
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
10
Registered human studies
Phase 4
Furthest phase reached
2,644
Planned or enrolled participants, across 9 studies that published a figure
Approved
FDA-approved product — VYLEESI (AUTOINJECTOR)
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What PT-141 is, and what it has been studied for
PT-141 is classified by ChEMBL as a protein, and appears in trial registrations under PT-141 and PT-141 FREE BASE. Its FDA substance identifier is 6Y24O4F92S.
Across 10 registered trials, it has been studied in Hypoactive Sexual Desire Disorder, Kidney Disease, Female Sexual Arousal Disorder and Sexual Arousal Disorder. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Palatin Technologies, Inc and Imperial College Healthcare NHS Trust among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
PT-141 reached Phase 4 across 10 registered trials.
An FDA-approved product contains PT-141. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying PT-141?
Papers published each year that name PT-141 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 5 | 0 | Yes |
| 2018 | 4 | 0 | Yes |
| 2019 | 6 | 2 | Yes |
| 2020 | 7 | 0 | Yes |
| 2021 | 10 | 1 | Yes |
| 2022 | 14 | 1 | Yes |
| 2023 | 8 | 0 | Yes |
| 2024 | 8 | 1 | Yes |
| 2025 | 12 | 1 | Yes |
| 2026 | 9 | 0 | No |
72 papers and 6 registered trials between 2017 and 2026. A paper counts when “bremelanotide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on PT-141
72 indexed papers name PT-141 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Bremelanotide
- Bremelanotide
- Bremelanotide: First Approval
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire
- Safety Profile of Bremelanotide Across the Clinical Development Program
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Collected 2026-08-02from PubMed, phrase-matched on “bremelanotide” in title and abstract. Run the same search.
About PT-141
A cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, and a metabolite of melanotan II — it differs from melanotan II by a C-terminal hydroxyl in place of the amide. It is an agonist at melanocortin receptors, with reported activity at MC1R, MC3R and MC4R.
- Also known as
- Bremelanotide
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.